Testis cancer markers: Clinical use;I marcatori sierici delle neoplasie del testicolo: Uso clinico

Minerva Medica

Volumn 93, Issue 5, 2002, Pages 365-369

  Salesi, N ^a   Di Cocco, B ^a   Alghisi, F ^b   Calabretta, F ^a   Bossone, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alpha feto proteins; Biological markers; Gonadotropins, chorionic; Lactate dehydrogenase; Testicular neoplasms, diagnosis

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

BLOOD LEVEL; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; HUMAN; MALE; MALE GENITAL TRACT CANCER; REVIEW; SEMINOMA; SERUM; TESTIS CANCER; TESTIS DISEASE;

ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN; GERMINOMA; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036818443     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. th Edition. New York: Wiley-Liss, 1997; p. 1-227.
2. Vaitukaitis JL. Human chorionic gonadotropin as a tumor marker. Ann Clin Lab Sci 1974;4:276-80.
3. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Boslin GJ. Advanced seminoma: Treatment result, survival and prognostic factors in 142 patients. J Clin Oncol 1994;12:120-6.
4. Fowler JE, Platoff GE, Kubrock CA, Stutzman RE. Commercial radioimmunoassay for beta subunit of human chorionic gonadotropin: Falsely positive determination due to elevated serum luteinizing hormone. Cancer 1982;49:136-9.
5. Odell WD, Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med 1987;317:1688-91.
6. Catalona WJ, Vaitakaitis JL, Fair WR. Falsely positive specific human chorionic gonadotropin assays in patients with testicular tumours: Conversion to negative with testosterone administration. J Urol 1979;122:126-8.
7. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Matzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotropin and alpha-fetoprotein during therapy. J Clin Oncol 2001;19:2534-41.
8. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poorrisk germ cell tumors. J Clin Oncol 1997;15:2546-52.
9. Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumor. J Natl Cancer Inst 1993;85:1828-35.
10. Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE. Marker half-life analisys as a prognostic tool in testicular cancer. J Urol 1981;128:708-11.
11. Stevens MJ, Norman Ar, Dearnaley DP, Horwich A. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 1995;13:87-92.
12. Von Eyben FE, Skude G, Fossa SD, Lepp O, Bormer O. Serum lactate dehydrogenase (S-LDH) and S-LDH isoenzymes in patients with testicular germ cell tumors. Mol Gen Genet 1983;189:326-33.
13. Von Eyben FE, Blaabjerg O, Petersen PH, Smith-Severtsen C, Gullberg B. Serum lactate dehydrogenase isoenzyme 1 are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours. Eur J Cancer 1992;238:410-5.
14. Finn E, Von Eyben, Liu FJ, Amato RJ, Fritsche HA. Lactate dehydrogenas isoenzyme 1 is the most important LD isoenzime in pazients with testicular germ cell tumor. Acta Oncol 2000;39(4):509-17.
15. Liu F, Fritsche H, Trujillo JM, Samuels ML. Serum lactate dehydrogenas isoenzime 1 in patients with advanced testicular cancer. Am J Clin Pathol 1982;78:178-83.
16. Weissbach L, Bussar-Maatz R, Mann K. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Eur Urol 1997;32(1):16-22.
17. Gels ME, Marrink J, Visser P, Sleijfer DT, Droste JH, Hoekstra HJ et al. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors. Ann Surg Oncol 1997;4(4):321-7.